OBJECTIVES: To evaluate whether patients with abnormal Reflux Symptom Index (RSI) and Reflux Finding Score (RFS) benefit from proton pump inhibitor (PPI) therapy. STUDY DESIGN: Open, multicenter, prospective longitudinal cohort study. METHODS: Patients with suspected reflux-associated laryngologic symptoms were evaluated by 40 community practice otolaryngologists using RSI and RFS. Patients were treated with pantoprazole 40-80 mg/d for 8-12 weeks if RSI was greater than 9 and RFS greater than 7. Pre- and posttherapeutic RSI and RFS were compared using Wilcoxon signed rank test and additionally controlled with the symmetry test of Bowker. RESULTS: A total of 1044 patients were included over a period of 20 months. Median total score of RSI before therapy was 12 and decreased to 3 (P≪0.001). Median total score of RFS before therapy was 16 and decreased to 6 (P≪0.001). Assessment of the treatment effect by otolaryngologists and patients was judged as being excellent in at least 50%. In 2% of the patients, gastrointestinal side effects were documented. CONCLUSION: RSI and RSF are easy to administer in the routine care of patients suspected of having laryngopharyngeal reflux. Patients identified by positive results of these tests have a high likelihood of excellent improvement after 8-12 weeks of PPI treatment. By implementation of RFS and RSI in daily use, most patients may not need time-consuming and cost-intensive examinations in the first-line assessment of LPR. These examinations can be reserved for nonresponders, and uncontrolled prescription of PPIs can be restricted.
OBJECTIVES: To evaluate whether patients with abnormal Reflux Symptom Index (RSI) and Reflux Finding Score (RFS) benefit from proton pump inhibitor (PPI) therapy. STUDY DESIGN: Open, multicenter, prospective longitudinal cohort study. METHODS:Patients with suspected reflux-associated laryngologic symptoms were evaluated by 40 community practice otolaryngologists using RSI and RFS. Patients were treated with pantoprazole 40-80 mg/d for 8-12 weeks if RSI was greater than 9 and RFS greater than 7. Pre- and posttherapeutic RSI and RFS were compared using Wilcoxon signed rank test and additionally controlled with the symmetry test of Bowker. RESULTS: A total of 1044 patients were included over a period of 20 months. Median total score of RSI before therapy was 12 and decreased to 3 (P≪0.001). Median total score of RFS before therapy was 16 and decreased to 6 (P≪0.001). Assessment of the treatment effect by otolaryngologists and patients was judged as being excellent in at least 50%. In 2% of the patients, gastrointestinal side effects were documented. CONCLUSION:RSI and RSF are easy to administer in the routine care of patients suspected of having laryngopharyngeal reflux. Patients identified by positive results of these tests have a high likelihood of excellent improvement after 8-12 weeks of PPI treatment. By implementation of RFS and RSI in daily use, most patients may not need time-consuming and cost-intensive examinations in the first-line assessment of LPR. These examinations can be reserved for nonresponders, and uncontrolled prescription of PPIs can be restricted.
Authors: Daniel R Witt; Huijun Chen; Jason D Mielens; Kieran E McAvoy; Fan Zhang; Matthew R Hoffman; Jack J Jiang Journal: J Voice Date: 2013-12-05 Impact factor: 2.009
Authors: Jérôme R Lechien; Camille Finck; Pedro Costa de Araujo; Kathy Huet; Véronique Delvaux; Myriam Piccaluga; Bernard Harmegnies; Sven Saussez Journal: Eur Arch Otorhinolaryngol Date: 2016-03-23 Impact factor: 2.503
Authors: Jerome R Lechien; Francois Mouawad; Maria R Barillari; Andrea Nacci; Seyyedeh Maryam Khoddami; Necati Enver; Sampath Kumar Raghunandhan; Christian Calvo-Henriquez; Young-Gyu Eun; Sven Saussez Journal: World J Clin Cases Date: 2019-10-06 Impact factor: 1.337